Butein | 2’,3,4,4’-tetrahydroxy Chalcone | EGFR/PDE Inhibitor

Butein/紫铆因 {[allProObj[0].p_purity_real_show]}

货号：A456537 同义名： 2’,3,4,4’-tetrahydroxy Chalcone

Butein 是一种从 Rhus verniciflua 中提取的植物多酚，是 cAMP 特异性的 PDE 抑制剂（IC50=10.4 μM）和蛋白酪氨酸激酶的抑制剂（对 EGFR 的 IC50=16 μM）。Butein通过 AKT 和 ERK/p38 MAPK 通路增强化疗药物的敏感性，并具有抗炎和抗癌活性。

Butein/紫铆因化学结构
CAS号：487-52-5

Butein/紫铆因 3D分子结构
CAS号：487-52-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

EGFR 亚型比较

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750/T790M), IC50: 14 nM EGFR (E746_A750), IC50: 2 nM						99%+
Daphnetin	+ EGFR, IC50: 7.67 μM					PKA,PKC	95%
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		98%
PD168393	++++ EGFR, IC50: 0.70 nM						99%+
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		98%
Norcantharidin	✔						98%
CL-387785	++++ EGFR, IC50: 370 pM						98%
WHI-P154	+++ EGFR, IC50: 4 nM					VEGFR,Src	98%
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	98%
AG 555	+ EGFR, IC50: 0.7 μM						98%
AG 494	+ EGFR, IC50: 1.2 μM						99%+
AG-556	+ EGFR, IC50: 5 μM						98%
RG13022	+ EGFR, IC50: 4 μM						99%+
Tyrphostin RG 14620	✔						99%+
Vandetanib	+ EGFR, IC50: 500 nM						99%
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		99%
AZD3759	++++ EGFR (L858R), IC50: 0.2 nM EGFR (WT), IC50: 0.3 nM						98%
Erlotinib	++++ EGFR, IC50: 2 nM						95%
Saracatinib	+++ EGFR (L861Q), IC50: 4 nM EGFR, IC50: 5 nM						99%+
AG1557	✔						99%
Rociletinib	++ EGFR (L858R/T790M), Ki: 21.5 nM EGFR (wt), Ki: 303.3 nM						98%
AG490	+ EGFR, IC50: 0.1 μM						98%
Cetuximab	++++ EGFR, Kd: 0.39 nM						95%
Osimertinib	++ WT EGFR, IC50: 12.92 nM L858R/T790M EGFR, IC50: 11.44 nM						98%
Osimertinib mesylate	✔						98% (Content MsOH 15.2-18.2%)
Chrysophanol	✔					mTOR	98%
PD153035	++++ EGFR, Ki: 5.2 pM						99%+
Olmutinib	✔					BTK	99%+
WZ4002	++++ EGFR (L858R), IC50: 2 nM EGFR (L858R/T790M), IC50: 8 nM						99%+
Icotinib	+++ EGFR, IC50: 5 nM						99%
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						98%
Cyasterone	✔						99%+
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						98%
WZ8040	✔						99%+
(-)-Epigallocatechin Gallate	✔						99%
AG 18	+ EGFR, IC50: 35 μM						99%+
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						99%
Falnidamol	✔						99%+
AZ-5104	++++ EGFR (L861Q) , IC50: <1 nM EGFR (L858R), IC50: 6 nM		+++ ErbB4, IC50: 7 nM			BRK	99%+
Butein	✔						95%
Genistein	✔						98%
SU5214	+ EGFR, IC50: 36.7 μM						99%+
Naquotinib	✔						99%+
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		98%
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		99%
Lazertinib	++++ WT EGFR, IC50: 76 nM L858R/T790M EGFR, IC50: 2 nM				++++ Del19/T790M, IC50: 1.7 nM		99%+
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						99%+
MTX-211	✔					PI3K	98%
(E)-AG 99	✔						99%+
Licochalcone D	✔					PARP,Caspase	99%
Zipalertinib	+++ EGFR (L861Q), IC50: 4.1 nM EGFR WT, IC50: 8 nM		+++ HER4, IC50: 4 nM		++++ EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM		97%
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		99%+
Firmonertinib mesylate	✔						99%+
Tyrphostin AG30	✔						99%+
EGFR-IN-12	++ EGFR, IC50: 21 nM						99%+
Mobocertinib	✔						98%
(Rac)-JBJ-04-125-02	✔						95%
(S)-Sunvozertinib	✔						99%
BLU-945	✔						95%
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			98%
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			99%+
ARRY-380 analog				✔			99%
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			99%+
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			98%
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			99%+
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			95%
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			98%
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms/CSF1R	98+%
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^L858R/T790M, IC50: 0.51 nM EGFR^T790M, IC50: 0.79 nM		98+%
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	98%
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			98%
Tucatinib				+++ ErbB2, IC50: 8 nM			98%
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Raf,Src	99%+
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			99%+
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	99%+
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			99%+
Afatinib dimaleate	++++ EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM			++ HER2, IC50: 14 nM			98%
Canertinib 2HCl	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			99%
Allitinib tosylate	++++ EGFR (T790M/L858R), IC50: 12 nM EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			97%
Afatinib	++++ EGFR (L858R), IC50: 10 nM EGFR (wt), IC50: 0.5 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			99%
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			98%
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			99%
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			99%
ALK-IN-1					++ EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM	ALK	99%
Brigatinib					+ EGFR(C797S/T790M/del19), IC50: 67.2 nM EGFR(del19), IC50: 39.9 nM	ALK,FLT3	98%
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	99%+
EAI045					✔		97%
Almonertinib					✔		99%
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		99%+
EGFR-IN-7					++++ EGFR^L858R/T790M, IC50: 0.19 nM EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Butein/紫铆因生物活性

靶点

EGFR/ErbB1

描述

Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4^[1]. In vitro, Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells^[2]. Otherwise, Butein also sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a^[3].

体内研究

In vivo, a combination treatment of Butein (2 mg/kg every 2 days) and cisplatin (2 mg/kg every 2 days) for three weeks notably suppresses tumor growth^[3].

体外研究

Butein potently inhibits cAMP-specific phosphodiesterase (type IV) activity with an IC50 of 10.4±0.4 μM. Otherwise, Butein exhibits broader inhibition across PDE types I, III, and V only at concentrations exceeding 100 μM^[1].

Butein (10, 20, and 40 μM; 24, 48, and 72 hours) inhibits cell growth in a dose- and time-dependent manner^[3]. Butein exhibits anticancer activity through the inhibition of the activation of PKB/AKT and MAPK pathways, which are two pathways known to be involved in resistance to cisplatin. Butein (20 μM) decreases phosphorylation of AKT, ERK and p38 following 24 h of co-treatment with Cisplatin (20 μM)^[3].

Butein/紫铆因细胞实验

Cell Line Huh-7 C3H10T1/2 adipocytes HCC-1569 BT-474 HCC-2218 HCC-1419 SKBR-3 T47D MCF-7 Primary cultured astrocytes Hep3B HepG2 HBE cells H1299 cells SPC-A1 cells PC-9 cells A549 cells C3H10T1/2 adipocytes Hepatoma cells (HepG2) Hepatic stellate cells (CFSC-2G) Primary mouse hippocampal neurons BV2 microglial cells HT22 mouse hippocampal cells H9c2 cardiomyoblasts H9c2 cardiomyoblasts	Concentration	Treated Time	Description	References
Huh-7	10-60 μM	24-96 h	Inhibited cell proliferation and colony formation	Int J Biol Sci. 2018 Sep 7;14(11):1521-1534.
C3H10T1/2 adipocytes	20 μM	6 h	Induction of Ucp1 mRNA expression, increased mitochondrial contents, and decreased numbers of large lipid droplets	Nat Chem Biol. 2016 Jul;12(7):479-81.
HCC-1569	10 μg/ml	24 h	To evaluate the effect of Butein on apoptosis of breast cancer cells, results showed that Butein induced apoptosis in HCC-1569 cells	J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.
BT-474	10 μg/ml	24 h	To evaluate the effect of Butein on apoptosis of breast cancer cells, results showed that Butein induced apoptosis in BT-474 cells	J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.
HCC-2218	1 ng/ml to 100 μg/ml	48 h	To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein did not significantly affect the viability of HCC-2218 cells	J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.
HCC-1419	1 ng/ml to 100 μg/ml	48 h	To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein did not significantly affect the viability of HCC-1419 cells	J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.
SKBR-3	1 ng/ml to 100 μg/ml	48 h	To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein did not significantly affect the viability of SKBR-3 cells	J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.
T47D	1 ng/ml to 100 μg/ml	48 h	To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein reduced the viability of T47D cells	J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.
MCF-7	1 ng/ml to 100 μg/ml	48 h	To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein reduced the viability of MCF-7 cells	J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.
Primary cultured astrocytes	50 µM	4 h	Inhibited TNF-α-induced pro-inflammatory mediator expression	J Neuroinflammation. 2023 Sep 6;20(1):203.
Hep3B	10-60 μM	24-96 h	Inhibited cell proliferation and colony formation, induced G2/M arrest and apoptosis	Int J Biol Sci. 2018 Sep 7;14(11):1521-1534.
HepG2	10-60 μM	24-96 h	Inhibited cell proliferation and colony formation, induced G2/M arrest and apoptosis	Int J Biol Sci. 2018 Sep 7;14(11):1521-1534.
HBE cells	20 μM, 40 μM, 60 μM	24 h or 48 h	Butein significantly decreased HBE cell viability.	Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.
H1299 cells	20 μM, 40 μM, 60 μM	24 h or 48 h	Butein significantly decreased NSCLC cell viability and induced cell apoptosis and G2/M phase arrest.	Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.
SPC-A1 cells	20 μM, 40 μM, 60 μM	24 h or 48 h	Butein significantly decreased NSCLC cell viability and induced cell apoptosis and G2/M phase arrest.	Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.
PC-9 cells	20 μM, 40 μM, 60 μM	24 h or 48 h	Butein significantly decreased NSCLC cell viability and induced cell apoptosis and G2/M phase arrest.	Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.
A549 cells	20 μM, 40 μM, 60 μM	24 h or 48 h	Butein significantly decreased NSCLC cell viability and induced cell apoptosis and G2/M phase arrest.	Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.
C3H10T1/2 adipocytes	20 μM	6 h	To investigate the effect of Butein on the PI3Kα-Akt1 signaling pathway, results showed that Butein increased Prdm4 and Ucp1 expression by inhibiting PI3Kα activity.	Cell Death Dis. 2018 Aug 29;9(9):876.
Hepatoma cells (HepG2)	1-10 μM	24 h	Butein protected HepG2 cells against ethanol- or acetaldehyde-induced toxicity and inhibited ROS production.	J Gastroenterol. 2013 Feb;48(2):222-37.
Hepatic stellate cells (CFSC-2G)	1-10 μM	24 h	Butein protected hepatic stellate cells against ethanol- or acetaldehyde-induced toxicity, inhibited ROS production, and suppressed α-SMA and procollagen I production.	J Gastroenterol. 2013 Feb;48(2):222-37.
Primary mouse hippocampal neurons	5 or 10 μM	24 h	Butein decreased glutamate-induced oxidative damage and ROS production in primary mouse hippocampal neurons.	Br J Pharmacol. 2016 Oct;173(19):2894-909.
BV2 microglial cells	1-10 μM	12-24 h	Butein suppressed LPS-induced pro-inflammatory enzymes and mediators in BV2 microglia, including IL-6, IL-1β, and TNF-α production and mRNA expression.	Br J Pharmacol. 2016 Oct;173(19):2894-909.
HT22 mouse hippocampal cells	1-10 μM	12-24 h	Butein decreased glutamate-induced oxidative injury and ROS production in HT22 cells and increased the expression of Bcl-2 and Bcl-xL.	Br J Pharmacol. 2016 Oct;173(19):2894-909.
H9c2 cardiomyoblasts	1, 3, 5 µM	24 h	To assess the protective effect of Butein against H2O2-induced oxidative stress. Butein pretreatment significantly increased the survival rate of H2O2-treated cells, reduced ROS production and apoptosis, and increased the expression of antioxidant proteins.	Antioxidants (Basel). 2022 Jul 23;11(8):1430.
H9c2 cardiomyoblasts	0.5-10 µM	24, 48, 72 h	To evaluate the cytotoxicity of Butein on H9c2 cardiomyoblasts. Results showed that all concentrations and durations of Butein treatment did not significantly alter cell viability.	Antioxidants (Basel). 2022 Jul 23;11(8):1430.

Cell Line

Concentration

Treated Time

Description

References

Huh-7

10-60 μM

24-96 h

Inhibited cell proliferation and colony formation

Int J Biol Sci. 2018 Sep 7;14(11):1521-1534.

C3H10T1/2 adipocytes

20 μM

6 h

Induction of Ucp1 mRNA expression, increased mitochondrial contents, and decreased numbers of large lipid droplets

Nat Chem Biol. 2016 Jul;12(7):479-81.

HCC-1569

10 μg/ml

24 h

To evaluate the effect of Butein on apoptosis of breast cancer cells, results showed that Butein induced apoptosis in HCC-1569 cells

J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.

BT-474

10 μg/ml

24 h

To evaluate the effect of Butein on apoptosis of breast cancer cells, results showed that Butein induced apoptosis in BT-474 cells

J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.

HCC-2218

1 ng/ml to 100 μg/ml

48 h

To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein did not significantly affect the viability of HCC-2218 cells

J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.

HCC-1419

1 ng/ml to 100 μg/ml

48 h

To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein did not significantly affect the viability of HCC-1419 cells

J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.

SKBR-3

1 ng/ml to 100 μg/ml

48 h

To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein did not significantly affect the viability of SKBR-3 cells

J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.

T47D

1 ng/ml to 100 μg/ml

48 h

To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein reduced the viability of T47D cells

J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.

MCF-7

1 ng/ml to 100 μg/ml

48 h

To evaluate the effect of Butein on the viability of breast cancer cells, results showed that Butein reduced the viability of MCF-7 cells

J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.

Primary cultured astrocytes

50 µM

4 h

Inhibited TNF-α-induced pro-inflammatory mediator expression

J Neuroinflammation. 2023 Sep 6;20(1):203.

Hep3B

10-60 μM

24-96 h

Inhibited cell proliferation and colony formation, induced G2/M arrest and apoptosis

Int J Biol Sci. 2018 Sep 7;14(11):1521-1534.

HepG2

10-60 μM

24-96 h

Inhibited cell proliferation and colony formation, induced G2/M arrest and apoptosis

Int J Biol Sci. 2018 Sep 7;14(11):1521-1534.

HBE cells

20 μM, 40 μM, 60 μM

24 h or 48 h

Butein significantly decreased HBE cell viability.

Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.

H1299 cells

20 μM, 40 μM, 60 μM

24 h or 48 h

Butein significantly decreased NSCLC cell viability and induced cell apoptosis and G2/M phase arrest.

Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.

SPC-A1 cells

20 μM, 40 μM, 60 μM

24 h or 48 h

Butein significantly decreased NSCLC cell viability and induced cell apoptosis and G2/M phase arrest.

Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.

PC-9 cells

20 μM, 40 μM, 60 μM

24 h or 48 h

Butein significantly decreased NSCLC cell viability and induced cell apoptosis and G2/M phase arrest.

Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.

A549 cells

20 μM, 40 μM, 60 μM

24 h or 48 h

Butein significantly decreased NSCLC cell viability and induced cell apoptosis and G2/M phase arrest.

Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.

C3H10T1/2 adipocytes

20 μM

6 h

To investigate the effect of Butein on the PI3Kα-Akt1 signaling pathway, results showed that Butein increased Prdm4 and Ucp1 expression by inhibiting PI3Kα activity.

Cell Death Dis. 2018 Aug 29;9(9):876.

Hepatoma cells (HepG2)

1-10 μM

24 h

Butein protected HepG2 cells against ethanol- or acetaldehyde-induced toxicity and inhibited ROS production.

J Gastroenterol. 2013 Feb;48(2):222-37.

Hepatic stellate cells (CFSC-2G)

1-10 μM

24 h

Butein protected hepatic stellate cells against ethanol- or acetaldehyde-induced toxicity, inhibited ROS production, and suppressed α-SMA and procollagen I production.

J Gastroenterol. 2013 Feb;48(2):222-37.

Primary mouse hippocampal neurons

5 or 10 μM

24 h

Butein decreased glutamate-induced oxidative damage and ROS production in primary mouse hippocampal neurons.

Br J Pharmacol. 2016 Oct;173(19):2894-909.

BV2 microglial cells

1-10 μM

12-24 h

Butein suppressed LPS-induced pro-inflammatory enzymes and mediators in BV2 microglia, including IL-6, IL-1β, and TNF-α production and mRNA expression.

Br J Pharmacol. 2016 Oct;173(19):2894-909.

HT22 mouse hippocampal cells

1-10 μM

12-24 h

Butein decreased glutamate-induced oxidative injury and ROS production in HT22 cells and increased the expression of Bcl-2 and Bcl-xL.

Br J Pharmacol. 2016 Oct;173(19):2894-909.

H9c2 cardiomyoblasts

1, 3, 5 µM

24 h

To assess the protective effect of Butein against H2O2-induced oxidative stress. Butein pretreatment significantly increased the survival rate of H2O2-treated cells, reduced ROS production and apoptosis, and increased the expression of antioxidant proteins.

Antioxidants (Basel). 2022 Jul 23;11(8):1430.

H9c2 cardiomyoblasts

0.5-10 µM

24, 48, 72 h

To evaluate the cytotoxicity of Butein on H9c2 cardiomyoblasts. Results showed that all concentrations and durations of Butein treatment did not significantly alter cell viability.

Antioxidants (Basel). 2022 Jul 23;11(8):1430.

Butein/紫铆因动物实验

Species Nude mice Nude mice Nude mice C57BL/6J mice	Animal Model Breast cancer xenograft model HCC xenograft model PC-9 xenograft model High-fat diet-induced obese mouse model	Administration	Dosage	Frequency	Description	References
Nude mice	Breast cancer xenograft model	Subcutaneous injection	10 μg/ml	Twice a week for 20 days	To evaluate the effect of Butein on in vivo breast cancer tumor growth, results showed that Butein inhibited the growth of BT-474 tumors but had no significant effect on HCC-1419 tumor growth	J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.
Nude mice	HCC xenograft model	Oral	10 mg/kg	Once daily for several weeks	Inhibited tumor growth and decreased expressions of Ki67 and phosphor-histone H3	Int J Biol Sci. 2018 Sep 7;14(11):1521-1534.
Nude mice	PC-9 xenograft model	Intraperitoneal injection	10 mg/kg	Once daily for 28 days	Butein significantly inhibited the growth of PC-9 xenografts by activating ER stress-dependent ROS generation and apoptosis pathways.	Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.
C57BL/6J mice	High-fat diet-induced obese mouse model	Intraperitoneal injection	5 mg/kg or 15 mg/kg per day	Once daily for 8 weeks	To investigate the effect of Butein on body weight gain and metabolism in high-fat diet-induced obese mice, results showed that Butein significantly reduced body weight gain and improved metabolic profiles.	Cell Death Dis. 2018 Aug 29;9(9):876.

Species

Nude mice Nude mice Nude mice C57BL/6J mice

Animal Model

Breast cancer xenograft model HCC xenograft model PC-9 xenograft model High-fat diet-induced obese mouse model

Administration

Dosage

Frequency

Description

References

Nude mice

Breast cancer xenograft model

Subcutaneous injection

10 μg/ml

Twice a week for 20 days

To evaluate the effect of Butein on in vivo breast cancer tumor growth, results showed that Butein inhibited the growth of BT-474 tumors but had no significant effect on HCC-1419 tumor growth

J Exp Clin Cancer Res. 2014 Jun 11;33(1):51.

Nude mice

HCC xenograft model

Oral

10 mg/kg

Once daily for several weeks

Inhibited tumor growth and decreased expressions of Ki67 and phosphor-histone H3

Int J Biol Sci. 2018 Sep 7;14(11):1521-1534.

Nude mice

PC-9 xenograft model

Intraperitoneal injection

10 mg/kg

Once daily for 28 days

Butein significantly inhibited the growth of PC-9 xenografts by activating ER stress-dependent ROS generation and apoptosis pathways.

Int J Biol Sci. 2019 Jun 4;15(8):1637-1653.

C57BL/6J mice

High-fat diet-induced obese mouse model

Intraperitoneal injection

5 mg/kg or 15 mg/kg per day

Once daily for 8 weeks

To investigate the effect of Butein on body weight gain and metabolism in high-fat diet-induced obese mice, results showed that Butein significantly reduced body weight gain and improved metabolic profiles.

Cell Death Dis. 2018 Aug 29;9(9):876.

Butein/紫铆因参考文献

Butein/紫铆因实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.67mL

0.73mL

0.37mL

18.37mL

3.67mL

1.84mL

36.73mL

7.35mL

3.67mL

Butein/紫铆因技术信息

CAS号	487-52-5
分子式	C₁₅H₁₂O₅
分子量	272.25
SMILES Code	OC1=CC=C(C(/C=C/C2=CC(O)=C(O)C=C2)=O)C(O)=C1
MDL No.	MFCD00017300

别名	2’,3,4,4’-tetrahydroxy Chalcone
运输	蓝冰
InChI Key	AYMYWHCQALZEGT-ORCRQEGFSA-N
Pubchem ID	5281222

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 50 mg/mL(183.65 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

Butein/紫铆因 {[allProObj[0].p_purity_real_show]}

Butein/紫铆因纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Butein/紫铆因质控信息

Butein/紫铆因生物活性

Butein/紫铆因细胞实验

Butein/紫铆因动物实验

Butein/紫铆因参考文献

Butein/紫铆因实验方案

Butein/紫铆因技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Butein/紫铆因 {[allProObj[0].p_purity_real_show]}

Butein/紫铆因 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Butein/紫铆因 质控信息

Butein/紫铆因 生物活性

Butein/紫铆因 细胞实验

Butein/紫铆因 动物实验

Butein/紫铆因 参考文献

Butein/紫铆因 实验方案

Butein/紫铆因 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Butein/紫铆因纯度/质量文件产品仅供科研

Butein/紫铆因质控信息

Butein/紫铆因生物活性

Butein/紫铆因细胞实验

Butein/紫铆因动物实验

Butein/紫铆因参考文献

Butein/紫铆因实验方案

Butein/紫铆因技术信息